Samyang Biopharmaceuticals Corporation originated as the pharmaceutical business unit of Samyang Corporation in 1995. In 2011, it separated from Samyang Corporation and became Samyang Biopharm. Subsequently, in 2021, it merged with Samyang Holdings, the holding company, with the goal of enhancing mid and long-term corporate values and establishing itself as a global biopharmaceutical company. The company's headquarters are situated in South Korea. Samyang Biopharmaceuticals focuses its business activities in the areas of medical devices, pharmaceutical products, and gene therapeutics.

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Urogenital Diseases

Small molecule drug

mRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5

Top 5 Drug Type	Count

Small molecule drug	6
mRNA	2

Top 5 Target	Count

Tubulin	1

Drugs associated with Samyang Biopharmaceuticals Corp.

Docetaxel polymeric micelle

Target

Tubulin

Mechanism

Tubulin modulators [+2]

Active Org.

Shandong Hubble Kisen Biological Technology Co Ltd [+3]

Originator Org.

Samyang Biopharmaceuticals Corp.

Active Indication

Bladder Cancer [+4]

Inactive Indication

Non-Muscle Invasive Bladder Neoplasms [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jul 2016

B-5626

Target-

Mechanism-

Active Org.

Samyang Biopharmaceuticals Corp.

Originator Org.

Samyang Biopharmaceuticals Corp.

Active Indication

Breast Cancer [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 2006

Capsaicin

Target

TRPV1

Mechanism

TRPV1 agonists

Active Org.

Propella Therapeutics, Inc. [+5]

Originator Org.

NeurogesX Pharmaceuticals PLC

Active Indication

Diabetic peripheral neuropathic pain [+10]

Inactive Indication

Hallux Valgus [+12]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date24 Jan 2003

Clinical Trials associated with Samyang Biopharmaceuticals Corp.

NCT06402058 / Not yet recruitingNot Applicable

A Randomized, Subject and Evaluator Blinded, Matched Pairs, Pilot Study to Evaluate the Safety and Efficacy of DMSB01 According to the Number of Injections in Subjects With Crow's Feet Lines Compared to Control Device

The objective of this Pilot Study is to verify the safety and efficacy of DMSB01 in the temporary improvement of Crow's Feet Lines

Start Date10 Jun 2024

Sponsor / Collaborator

Samyang Biopharmaceuticals Corp.

NCT06295172 / Not yet recruitingNot Applicable

A Randomized, Evaluator-blind, Matched Pairs, Prospective, Non Inferiority, Confirmatory Study to Compare the Safety and Efficacy Between Lafullen15 and Lafullen in the Correction of Nasolabial Folds

The objective of this clinical trial is to verify the safety and efficacy of Lafullen15 in the temporary improvement of nasolabial Folds

Start Date27 May 2024

Sponsor / Collaborator

Samyang Biopharmaceuticals Corp.

NCT06093321 / RecruitingNot Applicable

A Randomized, Blinded, Active-Controlled, Matched Pairs, Single-Institution, Non-Inferiority Trial to Compare and Evaluate the Efficacy and Safety of SYB PDO Thread and MINT Lift® for Temporarily Improvement of Nasolabial Folds

The objective of this clinical trial is to verify the safety and efficacy of SYB PDO Thread in the temporary improvement of nasolabial Folds.

Start Date13 Nov 2023

Sponsor / Collaborator

Samyang Biopharmaceuticals Corp.

100 Clinical Results associated with Samyang Biopharmaceuticals Corp.

0 Patents (Medical) associated with Samyang Biopharmaceuticals Corp.

Literatures (Medical) associated with Samyang Biopharmaceuticals Corp.

31 Jul 2023·Gland surgery

The novel use and feasibility of hemostatic oxidized regenerated cellulose agent (SurgiGuard^®): multicenter retrospective study.

Article

Author: Park, Jong-Hwa ; Park, Jeong-Ik ; Rho, Seoung Yoon ; Jin, Miryung ; Choi, Sae Byeol ; Lee, Maria ; Kim, Hyun Koo ; Kim, Kyung Sik ; Yun, Sangchul ; Hong, Jae-Young

BackgroundSurgiGuard^® is an absorbent hemostatic agent based on oxidized regenerated cellulose. The efficacy, effects and safety of SurgiGuard^® are equivalent to existing hemostatic agents in animal experiments. This study was designed to confirm that the use of SurgiGuard^® alone is effective, safe and feasible compared to combination with other hemostatic methods.MethodsWe retrospectively reviewed clinical data from 12 surgery departments in seven tertiary centers in South Korea nationwide. All surgeries were performed between January and December 2018.ResultsA total of 807 patients were enrolled; 447 patients (55.4%) had comorbidities. The rate of major surgery (operative time ≥4 hours) was 44% (n=355 patients). Regarding the type of SurgiGuard^® used in surgery, more than 70% of minor surgeries used non-woven types. In major surgery, more than five SurgiGuards^® were used in 7.3% (26 patients), and the proportion of co-usage (with four other hemostatic products) was 19.7% (70 patients). The effectiveness score was higher when SurgiGuard^® was used alone in both major (5.3±0.5 vs. 5.1±0.6, P=0.048) and minor surgery (5.4±0.6 vs. 5.2±0.4, P<0.001). Seven patients had immediate re-bleeding, and all of them used SurgiGuard^® and other products together. Nine patients reported adverse effects, such as abscess, bleeding, or leg swelling, but we found no direct correlation with SurgiGuard^®.ConclusionsSurgiGuard^® exhibited greater effectiveness when used alone. No direct adverse effects associated with SurgiGuard^® use were reported, and SurgiGuard^® had stable feasibility. Prospective comparative studies are needed in the future.

01 Jan 2023·Gastric Cancer

Feasibility and safety of inserting transient biodegradable stents in the pylorus during pylorus-preserving gastrectomy for gastric cancer: a preliminary study in a porcine for proof of concept

Article

Author: Kwak, Yoon Jin ; Yoon, Hyesung ; Alzahrani, Fadhel Dhaifallah H ; Yoo, Ja Eun ; Park, Do Joong ; Choi, Jong-Ho ; Koo, Eunhee ; Park, Shin-Hoo ; Wang, Sen ; Wang, Chaojie ; Kim, Hyun Myong ; Alzahrani, Khalid Mohammed ; Kong, Seong-Ho ; Park, Ji-Hyeon ; Yang, Han-Kwang ; Lee, Hyuk-Joon

BACKGROUNDTo evaluate whether insertion of self-biodegradable stent into the pylorus to prevent delayed-gastric emptying after pylorus-preserving gastrectomy is feasible and safe through porcine experiment.METHODSSelf-biodegradable dumbbell-shaped pyloric stents were designed from absorbable suture materials: poly(glycolide-co-caprolactone) (PGCL) or poly-p-dioxanone (PPDO). After gastrotomy on ten pigs, each stent was inserted: two shams, four PGCL stents, and four PPDO stents. Body weight (Bwt), body temperature (BT), complete blood cell (CBC) count, and plain X-ray were evaluated. On postoperative day (POD) 13, euthanasia was performed for histologic evaluation.RESULTSOperation was successfully performed in all ten pigs. Without tagging suture, both stents migrated before POD 3. The migration was delayed up to POD 13, when the tagging sutures (-t) were applied between stent and stomach wall. Self-degradation of PGCL started from POD 3, and stents were completely excreted from the abdomen by POD 8. Although PPDO were also weakened as self-degradation progressed, its shape was maintained in gastrointestinal tract for 13 days. Unexpected sudden death occurred in the pig with PPDO-t2 on POD 10, which is more likely due to acute volvulus rather than stent-related complication. There was no significant difference between three groups in terms of Bwt, BT, CBC, and histology (sham vs. PGCL vs. PPDO, all p > 0.05).CONCLUSIONThe concept of biodegradable stents made of absorbent suture material seems feasible in porcine experiment. Among them, PGCL which has shown rapid absorption, appears to be a more suitable material for transient pyloric absorbable stent when considering safety aspect.

01 Jan 2022·The Korean Journal of Physiology & PharmacologyQ4 · MEDICINE

Gallic acid-mitochondria targeting sequence-H₃R₉ induces mitochondria-targeted cytoprotection

Q4 · MEDICINE

Article

Author: Han, Jin ; Ko, Kyung Soo ; Kim, Goo-Young ; Jessa, Flores ; Bae, Yoonhee

The development of selective targeting of drug molecules towards the mitochondria is an important issue related to therapy efficacy. In this study, we report that gallic acid (GA)-mitochondria targeting sequence (MTS)-H₃R₉ exhibits a dual role as a mitochondria-targeting vehicle with antioxidant activity for disease therapy. In viability assays, GA-MTS-H₃R₉ showed a better rescue action compared to that of MTS-H₃R₉. GA-MTS-H₃R₉ dramatically exhibited cell penetration and intercellular uptake compared to MTS and fit escape from lysosome release to the cytosol. We demonstrated the useful targeting of GA-MTS-H₃R₉ towards mitochondria in AC16 cells. Also, we observed that the antioxidant properties of mitochondrial-accrued GA-MTSH₃R₉ alleviated cell damage by reactive oxygen species production and disrupted mitochondrial membrane potential. GA-MTS-H₃R₉ showed a very increased cytoprotective effect against anticancer activity compared to that of MTS-H₃R₉. We showed that GA-MTS-H₃R₉ can act as a vehicle for mitochondria-targeting and as a reagent for therapeutic applications intended for cardiovascular disease treatment.

News (Medical) associated with Samyang Biopharmaceuticals Corp.

29 Nov 2022

·www.businesswire.com

Surgical Devices Pipeline Report, 2022 - Includes Stages of Development, Segments, Regions & Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Surgical Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive information about the Surgical Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Report Scope Extensive coverage of the Surgical Devices under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Surgical Devices and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry The report enables you to: Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Surgical Devices under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Surgical Devices Overview 3 Products under Development 3.1 Surgical Devices - Pipeline Products by Stage of Development 3.2 Surgical Devices - Pipeline Products by Segment 3.3 Surgical Devices - Pipeline Products by Territory 3.4 Surgical Devices - Pipeline Products by Regulatory Path 3.5 Surgical Devices - Pipeline Products by Estimated Approval Date 3.6 Surgical Devices - Ongoing Clinical Trials 4 Surgical Devices - Pipeline Products under Development by Companies 4.1 Surgical Devices Companies - Pipeline Products by Stage of Development 4.2 Surgical Devices - Pipeline Products by Stage of Development 5 Surgical Devices Companies and Product Overview 6 Surgical Devices - Recent Developments 7 Appendix 7.1 Methodology List of Tables Surgical Devices - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Segment Surgical Devices - Pipeline Products by Territory Surgical Devices - Pipeline Products by Regulatory Path Surgical Devices - Pipeline Products by Estimated Approval Date Surgical Devices - Ongoing Clinical Trials Surgical Devices Companies - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Stage of Development Glossary List of Figures Surgical Devices - Pipeline Products by Stage of Development Surgical Devices - Pipeline Products by Segment Surgical Devices - Pipeline Products by Territory Surgical Devices - Pipeline Products by Regulatory Path Surgical Devices - Pipeline Products by Estimated Approval Date Surgical Devices - Ongoing Clinical Trials Companies Mentioned 6S Medical LLC Abbott Operations Uruguay Srl Acoustic MedSystems Inc Aesculap Inc Anastom Surgical Anchora Medical Ltd Apercure Surgical Ltd Apollo Endosurgery Inc Applied Medical Resources Corporation Apyx Medical Corp Archon Medical Technologies LLC Augusta University Baxter International Inc BioTex Inc BriteSeed BTG International Inc Carnegie Mellon University Centre Hospitalier Universitaire de Nice Charite University Hospital of Berlin Chengdu Yurui Innovation Technology Co Ltd Colospan Ltd Control Medical Technology LLC Core Essence Orthopaedics, LLC Corporis Medical Covidien Ltd CR Bard Inc Creative Balloons GmbH Cryofocus Medtech Shanghai Co Ltd CT Resources Inc Cutera Inc Cypris Medical, Inc. Dartmouth College Deep Blue Medical Advances Inc Drexel University Emblation Ltd Embricon Ltd (Inactive) Endo Tools Therapeutics SA EndoEvolution, LLC Ethicon Endo-Surgery Inc ExpandoHeat LLC Fixit Medical Ltd Fogless International AB G.I. Windows Inc Galil Medical Ltd Garantis Genicon Inc GI Windows Medical Corp Grand Valley State University H. Lee Moffitt Cancer Center & Research Institute Inc Hangzhou Kangsheng Medical Equipment Co Ltd Hannover Medical School Harvard University Hospital for Special Surgery IceCure Medical Ltd Imperial College London Indian Institute of Technology Delhi Innovex Medical Co Ltd Integra LifeSciences Holdings Corp Intuitive Surgical Inc IonMed Ltd. Jinan Micro Intelligent Technology Co Ltd Johns Hopkins University Keren Medical Ltd. LeMaitre Vascular Inc Livsmed Inc LuSeed Vascular Lymphatica Medtech SA MagniFeel Surgical Instruments Mayo Clinic Mecmaan Healthcare Ltd Medical University of South Carolina MediShield B.V. Medtronic Plc Mel Frontier Co Ltd Meta Biomed Co Ltd Michigan State University Naval Medical Research Center Next Science Ltd NorthShore University Health System NOvate Medical Technologies, LLC NoviRad Inc NovoGI LTD Novolock Ltd Novuson Surgical, Inc. Ohio State University Oklahoma State University Olympus America Inc OV World Co Ltd Pacira BioSciences Inc Parker Hannifin Corp Pavmed Inc PetVivo Holdings Inc Physcient, Inc. Polytechnic University of Catalonia Pro-Dex Inc Queen Mary University of London Ra Medical Systems Inc Ramona Optics Inc Ratner BioMedical Inc Resultados y Calidad del Sistema Sanitario Publico de Andalucia Rice University Saint Louis University Samyang Biopharmaceuticals Corp Sanovas Inc Shanghai MicroPort Medical Group Co Ltd Shanghai Shengzhe Medical Technology Co Ltd Shanghai Yichao Medical Equipment Co Ltd Silmag SA simedeq Simon Fraser University StatLink Surgical STRATA Skin Sciences Inc Stryker Corp SurgyAid, LLC Sutura Inc Teleflex Inc Tepha Inc The Feinstein Institute for Medical Research TransMed7 LLC Trinity College Dublin University of Auckland University of California University of California Davis University of California Los Angeles University of California San Diego University of Central Florida University of Chicago University of Maryland University of Maryland Baltimore University of Minnesota University of Missouri University of North Carolina University of South Florida University of Strasbourg University of Texas at Austin University of Texas Medical Branch at Galveston University of Toledo University of Utah University of Virginia US Medical Innovations LLC USGI Medical Inc Vanderbilt University Vascular Insights LLC VB Devices Vessi Medical Ltd Viveve Medical Inc Viveve, Inc. Wake Forest Baptist Medical Center Weill Cornell Medical College West Virginia University X-Biomedical Inc For more information about this report visit https://www.researchandmarkets.com/r/ekyrrp Source: GlobalData

16 Nov 2022

·www.prnewswire.com

Samyang Holdings Biopharmaceuticals Division's Croquis Proves Efficacy and Safety in Global Webinar

Participated in 'IMCAS Academy' webinar hosted by the IMCAS for 3 consecutive years Brazilian dermatologists announced the superiority of Croquis, actively targeting the Latin American market Pre-registered and recorded the most significant number of simultaneous viewers with a single topic for the lifting thread SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ -- Samyang Holdings Biopharmaceuticals Division's lifting thread brand 'Croquis,' is actively targeting the Latin American market following the EU and expanding its market base. Samyang Holdings Biopharmaceuticals Division (CEO: Lee Young-Joon) announced on November 2nd that it held a webinar at the 'IMCAS Academy' to inform the safety and efficacy of Croquis and introduced the procedure. International Master Course on Aging Science (IMCAS) is one of the world's three major medical aesthetics conferences, where the experts share the latest trends and medical technology. The IMCAS Academy is an online lecture platform. Samyang Holdings presented the lifting procedure with medical experts under the 'Bio Stimulation & Lifting Effect with PDO* THREADS' at IMCAS. It received positive responses from the audience when announcing side effects, causes, preventions, and treatment methods. Samyang Holdings presented three Brazilian dermatologists 'Dr. Clara Santos,' 'Dr. Patrica Omiga,' and 'Dr. Fabiano Leal' as speakers to focus on the Latin American market. They are regarded and respected as influential specialists in the Brazilian medical aesthetics market based on their various clinical experiences. According to the Korea Trade-Investment Promotion Agency (KOTRA), Latin America is an emerging market that shows a significant growth rate every year. About 1,360 people pre-registered for the Croquis' webinar, and with 435 people simultaneously watching in real-time. This was the most significant number of people attending IMCAS Academy webinars specifically on the lifting thread, which confirmed the high interest for Croquis. Samyang Holdings announced global case study results for the lifting thread brand 'Croquis', proving its efficacy and safety with data. It signed sales contracts in 18 countries worldwide, including the EU, Japan, and Latin America. It is also in the process of obtaining regulatory marketing approval in the US. Croquis is gaining the trust of the global medical aesthetics industry by using data-oriented marketing. It is securing various data through clinical trials to prove the correlation between the effect of their treatments and the physical properties of the lifting thread for evidence-based marketing. SOURCE Samyang Holdings Corp.

Clinical Result

04 Jul 2022

·www.prnewswire.com

With Market Size Valued at $185.4 Million by 2026, it`s a Healthy Outlook for the Global Bulk Paclitaxel Market

SAN FRANCISCO, July 4, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Bulk Paclitaxel - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What's New for 2022? With Market Size Valued at $185.4 Million by 2026, it`s a Healthy Outlook for the Global Bulk Paclitaxel Market Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 17; Released: January 2022 Executive Pool: 1333 Companies: 33 - Players covered include Fresenius Kabi AG; Guilin Huiang Biochemistry Pharmaceutical Co., Ltd.; Hainan Yeshanyuan Pharmaceutical Co., Ltd.; Novasep Holding SAS; Phyton Biotech; Poly Medicure Ltd.; Samyang Biopharmaceuticals Corporation; ScinoPharm Taiwan Ltd.; Teva API, Inc.; Yunnan Hande Bio-tech Co., Ltd./Hande Bio-Source, Inc. (HBS) and Others. Coverage: All major geographies and key segments Segments: Product (Semi-Synthetic Paclitaxel API, Natural Paclitaxel API); Application (Ovarian Cancer, Breast Cancer, Cervical Cancer, Other Applications) Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa. Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry ABSTRACT- Global Bulk Paclitaxel Market to Reach $185.4 Million by 2026 Amid the COVID-19 crisis, the global market for Bulk Paclitaxel estimated at US$98.2 Million, is projected to reach a revised size of US$185.4 Million by 2026, growing at a CAGR of 10.9% over the analysis period. Natural Paclitaxel API, one of the segments analyzed in the report, is projected to record a 10.3% CAGR and reach US$68.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Semi-Synthetic Paclitaxel API segment is readjusted to a revised 11.2% CAGR for the next 7-year period. The U.S. Market is Estimated at $29.6 Million in 2021, While China is Forecast to Reach $38.3 Million by 2026 The Bulk Paclitaxel market in the U.S. is estimated at US$29.6 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$38.3 Million by the year 2026 trailing a CAGR of 14.3% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.6% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.6% CAGR. More MarketGlass™ Platform Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide. Our platform is free for qualified executives and is accessible from our website or via our just released mobile application on iOS or Android About Global Industry Analysts, Inc. & StrategyR™ Global Industry Analysts, Inc., () is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years. CONTACTS: Zak Ali Director, Corporate Communications Global Industry Analysts, Inc. Phone: 1-408-528-9966 Email: [email protected] LINKS Join Our Expert Panel Connect With Us on LinkedIn Follow Us on Twitter Journalists & Media [email protected] SOURCE Global Industry Analysts, Inc.

Collaborate

100 Deals associated with Samyang Biopharmaceuticals Corp.

100 Translational Medicine associated with Samyang Biopharmaceuticals Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

B-5626	Lung Cancer More	Approved
Docetaxel polymeric micelle ( Tubulin )	Head and Neck Neoplasms More	Approved
SYO-1644	Neoplasms More	Phase 1
SYO-1906	Vomiting More	Clinical
SYP-1261	Kidney Neoplasms More	Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis